⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer

Official Title: Randomized Phase II/III Trial of Second Line Chemotherapy Comparing CPT-11 Monotherapy Versus S-1/CPT-11 Combination for S-1 Refractory Gastric Cancer

Study ID: NCT00639327

Conditions

Gastric Cancer

Study Description

Brief Summary: The purpose of this study is compare overall survival of the test arm (CPT-11/S-1 combination) to the control arm (CPT-11 alone) in the subjects with S-1 refractory advanced gastric cancer.

Detailed Description: Standard chemotherapy for advanced gastric cancer (AGC) in the US is Cisplatin/5-FU (CF) or docetaxel/CF (DCF), is in Europe epirubicin/CF (ECF) or epirubicin/oxaliplatin/ capecitabine (EOX). Until 2006, there was no evidence of standard chemotherapy for AGC in Japan. In 2007, by the results of JCOG9912 trial (5-FU alone vs. CPT-11/CDDP vs S-1) and SPIRITS trial (S-1 alone vs. S-1/CDDP), S-1/CDDP is regarded as a new standard regimen in Japan. In 2008, by the results of TOP-002 trial (s-1 alone vs. S-1/CPT-11), S-1/CPT-11 could not show the superiority to S-1 alone. One of the other phase III trials, JACCRO GC-03 trial (S-1 alone vs. S-1/docetaxel, NCT00287768) is now ongoing. However, the position of CPT-11 in the treatment of AGC will be regarded as a second-line. In Japan there is a controversy for the treatment of S-1 refractory gastric cancer. The controversy is continuing S-1 (like FOLFOX to FOLFIRI) or not as a second-line. After the successful adjuvant S-1 results (ACTS-GC trial), the same problem will occur in the patients who are recurrent from adjuvant S-1. Then, we conducted a phase II/III trial of CPT-11 with or without S-1 in the treatment of first-line S-1 refractory AGC.

Eligibility

Minimum Age: 20 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Midori Municipal Hospital, Nagoya, Aichi, Japan

Nagoya City University Hospital, Nagoya, Aichi, Japan

Yamamoto Hospital, Noshiro, Akita, Japan

Hirosahi University Graduate School of Medicine, Hirosaki, Aomori, Japan

University of Fukui Faculty of Medical Scieneces Hospital, Yoshida-gun, Fukui, Japan

Nippon Steel Yawata Memorial Hospital, Kitakyusyu, Fukuoka, Japan

Kurume University Hospital, Kurume, Fukuoka, Japan

Gunma University Hospital, Maehashi, Gunma, Japan

Gunma Prefectural Cancer Center, Oota, Gunma, Japan

Fukuyama City Hospital, Fukuyama, Hiroshima, Japan

Asahikawa Medical College Department Medicine, Asahikawa, Hokkaido, Japan

Asahikawa Medical College Hospital, Asahikawa, Hokkaido, Japan

Hakodate Goryoukaku Hopsital, Hakodate, Hokkaido, Japan

National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan

Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan

Hyogo Prefectural Awaji Hospital, Sumoto, Hyogo, Japan

Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa, Japan

Kanazawa Medical University Hospital, Kawakita, Ishikawa, Japan

Iwate Prefectural Central Hospital, Morioka, Iwate, Japan

Iwate Medical University Hospital, Morioka, Iwate, Japan

Kagawa Medical University Hospital, Kida, Kagawa, Japan

Kirishima Medical Center, Kirishima, Kagoshima, Japan

Tokai University Hospital, Isehara, Kanagawa, Japan

St.Marianna University School Of Medicine Hospital, Kawasaki, Kanagawa, Japan

Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan

Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan

Citizen's General Medical Center attached to Yokohama City University, Yokohama, Kanagawa, Japan

Miyagi Cancer Center, Natori, Miyagi, Japan

Institute of Development,Aging and Cancer,Tohoku University, Sendai, Miyagi, Japan

Tohoku University School Of Medicine, Sendai, Miyagi, Japan

Sendai Medical Center, Sendai, Miyagi, Japan

Kaneda Hospital, Maniwa, Okayama, Japan

Rinku General Medical Center, Izumisano, Osaka, Japan

Kimen Municipal Hospital, Kimen, Osaka, Japan

Sakai Municipal Hospital, Sakai, Osaka, Japan

Osaka Rosai Hospital, Sakai, Osaka, Japan

Suita Municipal Hospital Website, Suita, Osaka, Japan

Yao City Hospital, Yao, Osaka, Japan

Saiseikai Shiga Hospital, Ritto, Shiga, Japan

Shimane University Faculty of Medicine, Izumo, Shimane, Japan

Matsue City Hospital, Matsue, Shimane, Japan

Dokkyo University School of Medecine, Shimotsuga, Tochigi, Japan

Nippon Medical School, Bunkyo-ku, Tokyo, Japan

Surugadai Nihon University Hospital, Chiyoda-ku, Tokyo, Japan

Teikyo University Hospital, Itabashi-ku, Tokyo, Japan

Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan

Toho University Ohhashi Medical Center, Meguro-ku, Tokyo, Japan

Toranomon Hospital, Minato-ku, Tokyo, Japan

The Jikei University, Minato-ku, Tokyo, Japan

International University of Health and Welfare Mita Hospital, Minato-ku, Tokyo, Japan

Toho University Omori Medical Center, Oota-ku, Tokyo, Japan

Keio University Hospital, Shinjuku-ku, Tokyo, Japan

Tokyo Women's Medical University Institute of Gastorenterology, Shinjuku-ku, Tokyo, Japan

Metropolitan Bokutoh Hospital, Sumida-ku, Tokyo, Japan

Tottori University Faculty of Medicine, Yonago, Tottori, Japan

Saiseikai Takaoka Hospital, Takaoka, Toyama, Japan

Kouseiren Takaoka Hospital, Takaoka, Toyama, Japan

Aichi Medical University Hospital, Aichi, , Japan

Nakadoori General Hospital, Akita, , Japan

Aomori Prefectural Central Hospital, Aomori, , Japan

ChibaUniversity Hospital, Chiba, , Japan

Fukui Red Cross Hospital, Fukui, , Japan

Saiseikai Hospital, Fukui, , Japan

Saiseikai Fukuoka General Hospital, Fukuoka, , Japan

National Hospital Organization Kyushu Medical Center, Fukuoka, , Japan

National Kyusyu Cancer Center, Fukuoka, , Japan

Kyusyu University Faculty of Medical Sciences, Fukuoka, , Japan

Fukushima Medical University, Fukushima, , Japan

Gifu Municipal Hospital, Gifu, , Japan

Gifu Prefectural General Medical Center, Gifu, , Japan

Graduate School of Medicine, Gifu University, Gifu, , Japan

Hiroshima University Hospital, Hiroshima, , Japan

Hiroshima University Research Institute for Radiation Biology and Medicine Tumor Surgery, Hiroshima, , Japan

National Hospital Organization Kagoshima Medical Center, Kagoshima, , Japan

Kochi Health Sciences Center, Kochi, , Japan

Kumamoto Medical University Hospital, Kumamoto, , Japan

Nagano Municipal Hospital, Nagano, , Japan

Niigata Prefectural Cancer Center, Niigata, , Japan

National Hospital Organization Okayama Medical Center, Okayama, , Japan

Kitano Hospital, Osaka, , Japan

Osaka City University Graduate School of Medicine, Osaka, , Japan

Osaka Koseinenkin Hospital, Osaka, , Japan

Osaka General Medical Center, Osaka, , Japan

Saga Prefectural Hospital Kouseikan, Saga, , Japan

Toyama Prefectural Center Hospital, Toyama, , Japan

Yamagata University Faculty Of Medicine, Yamagata, , Japan

Contact Details

Name: Masashi Fujii, M.D.,PhD

Affiliation: Surugadai Nihon University Hospital

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: